secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001171843-25-002952
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics: Tovecimig meets primary endpoint in BTC trial; Q1 net loss $16.6M
--------------------------------------------------------------------------------

- Tovecimig + paclitaxel achieved 17.1% ORR (incl. 1 complete response) vs 5.3% for paclitaxel alone (p=0.031) in Phase 2/3 BTC study.
- Secondary endpoints PFS, OS, DoR analyses expected Q4 2025; pre-specified event count not yet met.
- Q1 2025 net loss $16.6M ($0.12/sh), R&D $13.1M (+37% YoY), cash $113M providing runway into 2027.
- CTX-10726 (PD-1 x VEGF-A) pre-IND meeting completed; IND filing expected Q4 2025.
- CTX-8371 Phase 1 dose-escalation advanced to 4th cohort with no DLTs; preliminary data H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325002952/0001171843-25-002952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325002952/f8k_050725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer